Baseline and clinical characteristics of the cohort with primary refractory disease with available subsequent treatment
| . | No salvage ASCT (N = 33), n (%) . | Salvage ASCT (N = 34), n (%) . | Total (N = 67), n (%) . | P value . |
|---|---|---|---|---|
| Age (y) | .051 | |||
| Median (range) | 67.2 (27.1-85.5) | 60.9 (30.8-71.6) | 63.2 (27-85.5) | |
| Sex | .396 | |||
| Female | 17 (51.5) | 14 (41.2) | 31 (46.3) | |
| Male | 16 (48.5) | 20 (58.8) | 36 (53.7) | |
| ISS | .778 | |||
| 1 | 9 (32.1) | 7 (25.9) | 16 (29.1) | |
| 2 | 8 (28.6) | 10 (37.0) | 18 (32.7) | |
| 3 | 11 (39.3) | 10 (37.0) | 21 (38.2) | |
| R-ISS | .666 | |||
| 1 | 7 (28.0) | 4 (17.4) | 11 (22.9) | |
| 2 | 12 (48.0) | 12 (52.2) | 24 (50.0) | |
| 3 | 6 (24.0) | 7 (30.4) | 13 (27.1) | |
| Induction regimen | ||||
| VRd | 32 (97.0) | 29 (85.3) | 61 (91.0) | |
| KRd | 0 (0.0) | 4 (11.8) | 4 (6.0) | |
| Quadruplets | 1 (3.0) | 1 (2.9) | 2 (3.0) | |
| Heavy chain involved | ||||
| IgA | 3 (13.6) | 7 (31.8) | 10 (22.7) | |
| IgG | 18 (81.8) | 15 (68.2) | 33 (75.0) | |
| IgM | 1 (4.5) | 0 (0.0) | 1 (2.3) | |
| Light chain involved | ||||
| κ | 13 (41.9) | 22 (64.7) | 35 (53.8) | |
| λ | 18 (58.1) | 12 (35.3) | 30 (46.2) | |
| FISH (mSMART) | .688 | |||
| Standard-risk | 12 (42.9) | 14 (42.4) | 26 (42.6) | |
| High-risk | 13 (46.4) | 13 (39.4) | 26 (42.6) | |
| Double-hit | 3 (10.7) | 6 (18.2) | 9 (14.8) | |
| Clonal plasma cells in the BM | .277 | |||
| Median (range) | 57.5 (0-90) | 73 (0-99) | 65 (0-99) |
| . | No salvage ASCT (N = 33), n (%) . | Salvage ASCT (N = 34), n (%) . | Total (N = 67), n (%) . | P value . |
|---|---|---|---|---|
| Age (y) | .051 | |||
| Median (range) | 67.2 (27.1-85.5) | 60.9 (30.8-71.6) | 63.2 (27-85.5) | |
| Sex | .396 | |||
| Female | 17 (51.5) | 14 (41.2) | 31 (46.3) | |
| Male | 16 (48.5) | 20 (58.8) | 36 (53.7) | |
| ISS | .778 | |||
| 1 | 9 (32.1) | 7 (25.9) | 16 (29.1) | |
| 2 | 8 (28.6) | 10 (37.0) | 18 (32.7) | |
| 3 | 11 (39.3) | 10 (37.0) | 21 (38.2) | |
| R-ISS | .666 | |||
| 1 | 7 (28.0) | 4 (17.4) | 11 (22.9) | |
| 2 | 12 (48.0) | 12 (52.2) | 24 (50.0) | |
| 3 | 6 (24.0) | 7 (30.4) | 13 (27.1) | |
| Induction regimen | ||||
| VRd | 32 (97.0) | 29 (85.3) | 61 (91.0) | |
| KRd | 0 (0.0) | 4 (11.8) | 4 (6.0) | |
| Quadruplets | 1 (3.0) | 1 (2.9) | 2 (3.0) | |
| Heavy chain involved | ||||
| IgA | 3 (13.6) | 7 (31.8) | 10 (22.7) | |
| IgG | 18 (81.8) | 15 (68.2) | 33 (75.0) | |
| IgM | 1 (4.5) | 0 (0.0) | 1 (2.3) | |
| Light chain involved | ||||
| κ | 13 (41.9) | 22 (64.7) | 35 (53.8) | |
| λ | 18 (58.1) | 12 (35.3) | 30 (46.2) | |
| FISH (mSMART) | .688 | |||
| Standard-risk | 12 (42.9) | 14 (42.4) | 26 (42.6) | |
| High-risk | 13 (46.4) | 13 (39.4) | 26 (42.6) | |
| Double-hit | 3 (10.7) | 6 (18.2) | 9 (14.8) | |
| Clonal plasma cells in the BM | .277 | |||
| Median (range) | 57.5 (0-90) | 73 (0-99) | 65 (0-99) |